An overview of biomarkers in Alzheimer's disease

Yaoxue Xuebao

Volumn 47, Issue 5, 2012, Pages 551-557

  Rong, Xian Fang ^a   Wang, Xiao Liang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Alzheimer's disease; Biomarker; Translational medicine

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; GENOMIC DNA; TAU PROTEIN;

ALZHEIMER DISEASE; DISEASE COURSE; HUMAN; NEUROFIBRILLARY TANGLE; PROTEOMICS; REVIEW; SENILE PLAQUE;

ADIPOKINES; ALPHA 1-ANTITRYPSIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; FLUORODEOXYGLUCOSE F18; HUMANS; LECTINS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; POSITRON-EMISSION TOMOGRAPHY; PRESENILINS; TAU PROTEINS;

EID: 84863677042     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Alzheimer A, Stelzmann RA, Schnitzlein HN, et al. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde" [J]. Clin Anat, 1995, 8: 429-431.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics [J]. Science, 2002, 297: 353-356. (Pubitemid 34790756)
3. Reddy PH. Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics [J]. J Biomed Biotechnol, 2006, 2006: 31372.
4. Galasko D, Hansen LA, Katzman R, et al. Clinicalneuropathological correlations in Alzheimer's disease and related dementias [J]. Arch Neurol, 1994, 51: 888-895. (Pubitemid 24286043)
5. Britschgi M, Rufibach K, Huang SL, et al. Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome [J]. Mol Cell Proteomics, 2011, 10: M111. 008862.
6. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group [J]. Neurobiol Aging, 1998, 19: 109-116.
7. Gosselet F, Candela P, Cecchelli R, et al. Role of the blood-brain barrier in Alzheimer's disease [J]. Med Sci (Paris), 2011, 27: 987-992.
8. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease [J]. Lancet Neurol, 2003, 2: 605-613. (Pubitemid 37162569)
9. Strozyk D, Blennow K, White LR, et al. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study [J]. Neurology, 2003, 60: 652-656. (Pubitemid 36246085)
10. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain [J]. Arch Neurol, 2009, 66: 382-389.
11. Fukuyama R, Mizuno T, Mori S, et al. Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients [J]. Eur Neurol, 2000, 43: 155-160. (Pubitemid 30189537)
12. Buerger K, Ewers M, Pirttilä T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease [J]. Brain, 2006, 129: 3035-3041. (Pubitemid 44684523)
13. Hampel H, Bürger K, Pruessner JC, et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease [J]. Arch Neurol, 2005, 62: 770-773. (Pubitemid 40656092)
14. Riemenschneider M, Wagenpfeil S, Vanderstichele H, et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias [J]. Mol Psychiatry, 2003, 8: 343-347. (Pubitemid 36712928)
15. Buerger K, Zinkowski R, Teipel SJ, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 [J]. Arch Neurol, 2002, 59: 1267-1272. (Pubitemid 34856379)
16. Perrin RJ, Craig-Schapiro R, Malone JR, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease [J]. PLoS One, 2011, 6: e16032.
17. Zetterberg H, Andreasson U, Hansson O, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease [J]. Arch Neurol, 2008, 65: 1102-1107.
18. Zhong Z, Ewers M, Teipel S, et al. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment [J]. Arch Gen Psychiatry, 2007, 64: 718-726. (Pubitemid 46878672)
19. Ewers M, Zhong Z, Bürger K, et al. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease [J]. Brain, 2008, 131: 1252-1258.
20. Sjögren M, Davidsson P, Gottfries J, et al. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process [J]. Dement Geriatr Cogn Disord, 2001, 12: 257-264. (Pubitemid 32429725)
21. Irizarry MC. Biomarkers of Alzheimer disease in plasma [J]. NeuroRx, 2004, 1: 226-234. (Pubitemid 46591884)
22. Choi J, Malakowsky CA, Talent JM, et al. Identification of oxidized plasma proteins in Alzheimer's disease [J]. Biochem Biophys Res Commun, 2002, 293: 1566-1570. (Pubitemid 34681057)
23. Blennow K, Hampel H, Weiner M, et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease [J]. Nat Rev Neurol, 2010, 6: 131-144.
24. Liao PC, Yu L, Kuo CC, et al. Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease [J]. Proteomics Clin Appl, 2007, 1: 506-512.
25. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease [J]. N Engl J Med, 2002, 346:476-483. (Pubitemid 34441738)
26. Mancuso M, Orsucci D, Siciliano G, et al. Mitochondria, mitochondrial DNA and Alzheimer's disease. What comes first? [J]. Curr Alzheimer Res, 2008, 5: 457-468.
27. Quinn JF, Montine KS, Moore M, et al. Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease [J]. J Alzheimers Dis, 2004, 6: 93-97. (Pubitemid 38418561)
28. Brys M, Pirraglia F, Rich K, et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment [J]. Neurobiol Aging, 2009, 30: 682-690.
29. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study [J]. BMJ, 2001, 322: 1447-1451. (Pubitemid 32575406)
30. Zuliani G, Donnorso MP, Bosi C, et al. Plasma 24S-hydroxycholesterol levels in elderly subjects with late onset Alzheimer's disease or vascular dementia: a case-control study [J]. BMC Neurol, 2011, 11: 121.
31. Padmanabhan J, Levy M, Dickson DW, et al. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons [J]. Brain, 2006, 129: 3020-3034. (Pubitemid 44684522)
32. Abraham CR. Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease [J]. Neurobiol Aging, 2001, 22: 931--936.
33. Niimura M, Isoo N, Takasugi N, et al. Aph-1 contributes to the stabilization and trafficking of the gamma-secretase complex through mechanisms involving intermolecular and intramolecular interactions [J]. J Biol Chem, 2005, 280: 12967-12975.
34. Ezquerra M, Lleó A, Castellví M, et al. A novel mutation in the PSEN2 gene (T430M) associated with variable expression in a family with early-onset Alzheimer disease [J]. Arch Neurol, 2003, 60: 1149-1151. (Pubitemid 36975806)
35. Coon KD, Myers AJ, Craig DW, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease [J]. J Clin Psychiatry, 2007, 68: 613-618. (Pubitemid 46663046)
36. Bertram L. Alzheimer's disease genetics current status and future perspectives [J]. Int Rev Neurobiol, 2009, 84: 167-184.
37. Colacicco AM, Solfrizzi V, D'Introno A, et al. Alpha-2-macroglobulin gene, oxidized low-density lipoprotein receptor-1 locus, and sporadic Alzheimer's disease [J]. Neurobiol Aging, 2009, 30: 1518-1520.
38. Bottino CM, Castro CC, Gomes RL, et al. Volumetric MRI measurements can differentiate Alzheimer's disease, mild cognitive impairment, and normal aging [J]. Int Psychogeriatr, 2002, 14: 59-72. (Pubitemid 34625564)
39. Apostolova LG, Thompson PM. Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment [J]. Neuropsychologia, 2008, 46: 1597-1612.
40. Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias [J]. J Nucl Med, 2008,49: 390-398. (Pubitemid 351355204)
41. Pakrasi S, O'Brien JT. Emission tomography in dementia [J]. Nucl Med Commun, 2005, 26: 189-196. (Pubitemid 40411042)
42. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease [J]. Brain, 2007, 130: 2837-2844. (Pubitemid 350033975)
43. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease [J]. Brain, 2009, 132: 1355-1365.
44. Albert MS, Moss MB, Tanzi R, et al. Preclinical prediction of AD using neuropsychological tests [J]. J Int Neuropsychol Soc, 2001, 7:631-639. (Pubitemid 32700957)
45. O'Donnell J, Pietrzak RH, Ellis KC, et al. Understanding failure of visual paired associate learning in amnestic mild cognitive impairment [J]. J Clin Exp Neuropsychol, 2011, 33: 1069-1078.
46. Geraghty J. Adenomatous polyposis coli and translational medicine [J]. Lancet, 1996, 348: 422.
47. Liu Y, Hong L, Yu LS, et al. The role of ADME evaluation in translation research of innovative drug [J]. Acta Pharm Sin 2011, 46: 19-29.
48. Zhu L, Yu J, Shi Q, et al. Strain- and age-related alteration of proteins in the brain of SAMP8 and SAMR1 mice [J]. J Alzheimers Dis, 2011, 23: 641-654.